Skip to main content
. 2021 Feb 11;9(1):47–56. doi: 10.14744/nci.2021.65725

Table 1.

Patients’ and BM characteristics

Total
(n=41)
Characteristics of patients
 Age
  <65 61
  ≥65 39
 Sex (%)
  Male 53.7
  Female 46.3
 Primary tumor
  Colon 22
  Rectum 19.5
  Stomach 39
  Esophagus 4.9
  Pancreas 9.8
  Bile duct 2.4
  Rectosigmoid 2.4
 Histology
  Adenocarcinoma 90.2
  Squamous 4.9
  Neuroendocrine 4.9
 KPS* 60–90
 KPS
  ≤70 26.8
  >70 73.2
 ds-GPA score
  ds-GPA = 1 24.4
  ds-GPA = 2 43.9
  ds-GPA = 3 31.7
  ds-GPA = 4 0
 GI-GPA score
  GI-GPA = 0 24.4
  GI-GPA = 1 39
  GI-GPA = 2 29.3
  GI-GPA = 3 7.3
 RPA score
  2 73.2
  3 26.8
 Systemic disease status at diagnosis of BM
  Controlled 24.4
  Uncontrolled 75.6
 Extracranial metastasis
  Lung 48.8
  Bone 26.8
  Liver 46.3
  Systemic lymph node 29.3
  Skin 2.4
  Adrenal gland 7.3
 Interval from diagnosi to extracranial metastasis* 0–49
Characteristics of BM
 Interval from diagnosis to BM* (months) 0–60
 Number of metastasis
  1 39
  2 19.5
  ≥3 41.5
 Location of BM
  Supratentorial 48.8
  Infratentorial 29.3
  Both 22
 Volume of BM (cc)* 0.34–112
 Volume of BM (cc)
  <10 cc 51.2
  ≥10 cc 48.8
 Edema 75.6
 Hemorrhage 39
 Neurological symptoms
  Headache 48.7
  Ataxia 7.3
  Motor weakness 29.3
  Nausea 53.6
  Mental change 14.6
  Seizure 7.3
  Asymptomatic 2.4

*: Median (minimum–maximum); BM: Brain metastasis; ds-GPA: Diagnosis-specific graded prognostic assessment; GI-GPA: Gastrointestinal graded prognostic assessment; KPS: Karnofsky performance status.